Pay for Quality
Pay for Quality
Pay for Quality
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
84 <strong>Pay</strong> <strong>for</strong> <strong>Quality</strong> KCE Reports 118<br />
The current results are mainly based on a rapid increasing amount of experience in the<br />
USA and the UK. Although a number of start up countries were also included, they still<br />
are in such a premature phase that the lessons to be learned from their experience are<br />
still limited. However, where appropriate we will refer to their choices of P4Q design<br />
and implementation.<br />
Be<strong>for</strong>e discussing the results the following methodological limitations should be taken<br />
into account:<br />
Although the systematic review was per<strong>for</strong>med using multiple databases and several<br />
languages, there exist still other databases and languages which we were unable to<br />
check.<br />
The tool used <strong>for</strong> the quality appraisal to eliminate low quality primary studies was<br />
based on several existing validated tools, which were combined into a generic tool<br />
applicable to P4Q studies. The use of this combined tool is not validated as such.<br />
Because observational studies are the main source of in<strong>for</strong>mation on P4Q, it was<br />
decided to report P4Q results comprehensively, without a restriction to randomized<br />
designs. A distinction between strong and weak evidence was made. Selection bias can<br />
there<strong>for</strong>e not be excluded.<br />
Not all relevant contextual in<strong>for</strong>mation is available <strong>for</strong> each of the included studies. For<br />
example, leadership as a factor might impact P4Q results, but is rarely reported upon.<br />
As has become clear in the previous study description section, <strong>for</strong> the contextual<br />
factors, the P4Q intervention description and the process of implementation and<br />
communication, the completeness of reporting is often lacking in P4Q evaluation<br />
studies.<br />
The limitations in terms of review selection criteria have to be taken into account. A<br />
strict P4Q definition was used (e.g. public reporting is not considered to be a <strong>for</strong>m of<br />
P4Q). The population does not include studies outside a primary care or general<br />
hospital setting (e.g. psychiatric care and nursing homes).<br />
The limitations in terms of studies’ selection criteria have to be taken into account.<br />
With regard to context, studies are more per<strong>for</strong>med in urban areas than in rural areas.<br />
Since a number of studies use a minimal patient panel size per provider or per target <strong>for</strong><br />
each provider, it is likely that smaller practices are underrepresented. Furthermore,<br />
because many studies focus upon a stabile and regular type of patients, results may not<br />
be applicable <strong>for</strong> one time only and quickly physician switching patients. The same is<br />
true <strong>for</strong> patients who are exception reported in the UK system and are excluded from<br />
most UK study samples, because their per<strong>for</strong>mance data are rarely available.<br />
As described in chapter 4 (section 4.2.6), there is a general trend of quality<br />
improvement present in some of the countries where P4Q studies took place, like in<br />
the UK. Only results based on strong evidence take this trend into account to isolate<br />
the P4Q effect from the time trend effect. In addition, P4Q is an intervention that’s<br />
typically combined with other interventions. Because of the mix throughout all P4Q<br />
studies, it is impossible to separate the P4Q impact from the other concurrent quality<br />
improvement initiatives’ impact. The studies discussed here are always based on a<br />
‘bundled’ approach.<br />
P4Q is still a very recent phenomenon. For many medical conditions there is no P4Q<br />
evidence (urology, intensive care, geriatrics, most of surgical care, etc). Secondly, there<br />
are medical conditions <strong>for</strong> which some first evaluation attempts have been per<strong>for</strong>med,<br />
but <strong>for</strong> which the evidence is still scarce and no conclusions about P4Q effects can be<br />
drawn (urinary tract infections, skin infections, gastric infections, depression/mental<br />
illness, chronic child care, COPD, epilepsy, hyperthyroidism, chronic cancer care,<br />
osteoarthritis). In more generic terms the same can be said <strong>for</strong> the introduction of new<br />
drugs and <strong>for</strong> P4Q effects on the use of most care management processes when<br />
assessed separately.<br />
However, this still leaves a large group of target conditions <strong>for</strong> which evidence is<br />
available. The effects on the clinical effectiveness domain are reported firstly.